Unknown

Dataset Information

0

Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.


ABSTRACT:

Background

We conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory acute myeloid leukemia (RR-AML).

Methods

We performed a literature search on PubMed, Cochrane Library, and Clinicaltrials.gov. After screening 677 manuscripts, 13 studies were included. Data was extracted following PRISMA guidelines. Pooled analysis was done using the meta-package by Schwarzer et al. Proportions with 95% confidence intervals (CI) were computed.

Results

We analyzed 57 patients from 10 clinical trials and 3 case reports. The pooled complete and overall response rates were 49.5% (95% CI 0.18-0.81, I=65%) and 65.2% (95% CI 0.36-0.91, I=57%). The pooled incidence of cytokine release syndrome, immune-effector cell associated neurotoxicity syndrome, and graft-versus-host disease was estimated as 54.4% (95% CI 0.17-0.90, I=77%), 3.9% (95% CI 0.00-0.19, I=22%), and 1.6% (95%CI 0.00-0.21, I=33%), respectively.

Conclusion

CAR-T therapy has demonstrated modest efficacy in RR-AML. Major challenges include heterogeneous disease biology, lack of a unique targetable antigen, and immune exhaustion.

SUBMITTER: Shahzad M 

PROVIDER: S-EPMC10164930 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.

Shahzad Moazzam M   Nguyen Andrea A   Hussain Ali A   Ammad-Ud-Din Mohammad M   Faisal Muhammad Salman MS   Tariq Ezza E   Ali Fatima F   Butt Atif A   Anwar Iqra I   Chaudhary Sibgha Gull SG   Lutfi Forat F   Ahmed Nausheen N   Singh Anurag K AK   Hematti Peiman P   McGuirk Joseph P JP   Mushtaq Muhammad Umair MU  

Frontiers in immunology 20230424


<h4>Background</h4>We conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory acute myeloid leukemia (RR-AML).<h4>Methods</h4>We performed a literature search on PubMed, Cochrane Library, and Clinicaltrials.gov. After screening 677 manuscripts, 13 studies were included. Data was extracted following PRISMA guidelines. Pooled analysis was done using the meta-package by Schwarzer et al. Proportions with 9  ...[more]

Similar Datasets

| S-EPMC6624167 | biostudies-literature
| S-EPMC8815830 | biostudies-literature
| S-EPMC8171365 | biostudies-literature
| S-EPMC4426796 | biostudies-literature
| S-EPMC5576380 | biostudies-literature
| S-EPMC9809466 | biostudies-literature
| S-EPMC8833567 | biostudies-literature
| S-EPMC6406805 | biostudies-literature